For the quarter ending 2025-06-30.
| Income Statement | 2025-06-30 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| General and administrative | 657 | 754 | 2,074 | |
| Total operating expenses | 657 | 754 | 2,074 | |
| Loss from operations | -657 | -754 | -2,074 | |
| Other expense | -32 | -9 | - | |
| Other nonoperating expense | - | - | 19 | |
| Interest income | 0 | - | - | |
| Other expense, net | -32 | -9 | -19 | |
| Net loss | -689 | -763 | -2,093 | |
| Basic EPS | -0.65 | -0.83 | -2.29 | |
| Diluted EPS | -0.65 | -0.83 | -2.29 | |
| Basic Average Shares | 1,065,000 | 914,000 | 914,000 | |
| Diluted Average Shares | 1,065,000 | 914,000 | 914,000 | |
TITAN PHARMACEUTICALS INC (TTNP)
TITAN PHARMACEUTICALS INC (TTNP)